Update #03 – Performing Dose-response assays of BAY-299 on medulloblastoma
I have been screening multiple medulloblastoma cell lines including ONS-76, D425, D458, and Med8A with BAY-299 and its negative control probe. So far, three out of four lines have demonstrated sensitivity to the BAY-299 probe consistent with the screening results (Defining Epigenetic Drivers of Medulloblastoma Post 3 Dose Response – Zenodo). https://zenodo.org/record/3565891#.XfFkn5NKh4o
Future directions will involve ensuring that BAY-299 is not exhibiting an off target effect on other BRD family members and if it is on-target to determine whether TAF1 or BRD1 is responsible for BAY-299’s antiproliferative effect.